top of page
On the Scales

Semaglutide Skinny Shot

Vital Flow Now Offers Semaglutide Weekly Injections To Help You Achieve Your Fitness & Weight Goals

Screenshot 2024-02-20 at 10.40.49 AM.png

What is a Semaglutide Injection?

Semaglutide is an FDA-approved medication for Type 2 diabetes used to improve insulin resistance, with a side effect of long-term weight loss. While Semaglutide is commonly associated with the brand name Ozempic®, our offering distinguishes itself with a unique formulation tailored to optimize weight outcomes beyond conventional options.

A Woman Looking out of a Swimming Pool

Experience the Vital Flow Difference 

At Vital Flow, we now offer Semaglutide weekly injections designed to modulate gastric emptying rates. By prolonging the stomach's digestion process, signals of satiety are promptly relayed to the brain, inducing a notable suppression of appetite without reliance on stimulants. Leveraging the body's intrinsic insulin production, our approach harnesses the power of Semaglutide to facilitate sustained weight management. Furthermore, embracing a Semaglutide regimen not only fosters balanced blood sugar levels but also promotes enhanced vitality, potentially contributing to overall well-being.

Weekly Injection Dose

Monthly Price

Week 1 through Week 4: 0.25mg weekly

Week 5 through Week 8: 0.50mg weekly

Week 9 through Week 12: 1mg weekly

Week 13 through Week 16: 1.7mg weekly

- $400 per month with no hidden fees.
- Medication is shipped to you.
- Free Consult.  

Week 17 and on: 2.4mg weekly

A Pre-Assessment is Conducted Prior To Treatment

Semaglutide Side Effects

  • Nausea

  • Vomiting

  • Diarrhea

  • Abdominal Pain

  • Constipation

​

There are also less-common side effects, such as allergic reactions, kidney problems, and hypoglycemia. In some cases for individuals with heart problems it can damage the retina of the eye.

Contraindications and Education

Contraindications to Semaglutide

  • Medullary Thyroid Carcinoma

  • Multiple Endocrine Neoplasia syndrome type 2

Studies on Semaglutide

bottom of page